ANVS.US Annovis Bio Inc

Healthcare Biotechnology USA Stocks
0.9261 USD
Close of Nov 14, 2026
0.6200 5.50
Market cap
USD 39.8M
P/E
-
P/B
25.18x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ANVS.US undervalued?

Graham number

The Graham number of Annovis Bio Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Annovis Bio Inc fundamental analysis

No fundamental analysis for Annovis Bio Inc yet.

Annovis Bio Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Annovis Bio Inc

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to …

Full company profile